R
Ruben A. Mesa
Researcher at University of Texas Health Science Center at San Antonio
Publications - 720
Citations - 35662
Ruben A. Mesa is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 78, co-authored 632 publications receiving 30126 citations. Previous affiliations of Ruben A. Mesa include Wrocław Medical University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,
Ruben A. Mesa,Jason Gotlib,Vikas Gupta,John F. DiPersio,John Catalano,Michael W. Deininger,Alan L. Shields,Carole B. Miller,Richard T. Silver,Moshe Talpaz,Elliott F. Winton,Jimmie H. Harvey,Thomas Hare,Sue Erickson-Viitanen,William Sun,Victor Sandor,Richard S. Levy,Hagop M. Kantarjian,Srdan Verstovsek +18 more
TL;DR: Changes in SV as low as 10% in ruxolitinib-treated patients were associated with improvements on EORTC QLQ-C30 Global Health subscale, PROMISE Fatigue scale, and the MFSAF v2.0 diary TSS, and commensurate improvements in these outcomes were observed as the SV reduction increased.
Journal ArticleDOI
Ruxolitinib dose management as a key to long-term treatment success
TL;DR: Close monitoring of blood counts and careful dose management, particularly early in the course of therapy, are essential to avoid unnecessary cytopenias that may prompt premature treatment discontinuation by patients who otherwise would benefit from continued therapy.
Journal ArticleDOI
Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients
Srdan Verstovsek,Miklos Egyed,Ewa Lech-Marańda,Tomasz Sacha,Viviane Dubruille,Stephen T. Oh,Doroteya K. Todorieva-Todorova,Francesco Passamonti,Blanca Xicoy,Bjorn Andreasson,Daniel El Fassi,Claire N. Harrison,Donal P. McLornan,Mary Frances McMullin,Christof Scheid,Marianne Tang Severinsen,Mark Kowalski,Gregg Smith,Ruben A. Mesa +18 more
TL;DR: Momelotinib is a potent JAK1, JAK2 and ACVR1 inhibitor with clinical activity against the three hallmark features of myelofibrosis, demonstrating robust and consistent survival outcomes for patients who commenced JAKi therapy with MMB and those dosed initially with RUX/BAT followed by MMB.
Journal ArticleDOI
Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies
Ruben A. Mesa,Srdan Verstovsek,Francisco Cervantes,Roger J. Waltzman,Estella Mendelson,Nicolas Martin,William Sun,Victor Sandor,Richard S. Levy,Claire N. Harrison +9 more
TL;DR: In the COMFORT studies, ruxolitinib demonstrated significantly greater reductions in spleen size compared with placebo or BAT, and this post hoc analysis of the 2 studies shows that patients who received BAT in the COMfORT-II study had similar symptom and symptom scores.
Journal ArticleDOI
Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association
Sarah Friis Christensen,Robyn M. Scherber,Robyn M. Scherber,Nana Brochmann,Martin Goros,Jonathan Gelfond,Christen Lykkegaard Andersen,Esben Meulengracht Flachs,Ruben A. Mesa +8 more
TL;DR: A U-shaped association between BMI and Total Symptom Burden was observed in both datasets with significantly higher mean scores for underweight and obese patients relative to normal weight, as BMI is a potentially modifiable factor in the care of MPN patients.